Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 09/30/25
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)Seeking Alpha • 09/30/25
Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend DogsSeeking Alpha • 09/28/25
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)Business Wire • 09/25/25
BMY Reports Positive Data From a Late-Stage Multiple Myeloma StudyZacks Investment Research • 09/24/25
Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum TranscriptSeeking Alpha • 09/23/25
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple MyelomaBusiness Wire • 09/23/25
Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the USReuters • 09/22/25
Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To IncomeSeeking Alpha • 09/20/25
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?Zacks Investment Research • 09/19/25
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025Business Wire • 09/19/25
Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected DividendsSeeking Alpha • 09/18/25
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare ForumBusiness Wire • 09/16/25